NCT00313560View on ClinicalTrials.gov

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 16, 2006

Primary Completion Date

December 27, 2013

Study Completion Date

February 27, 2019

Conditions
Pancreatic Cancer
Interventions
DRUG

erlotinib hydrochloride

Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00313560 - ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA) | Biotech Hunter | Biotech Hunter